A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach

Abstract Background The epidermal growth factor receptor (EGFR) overexpression is found in metastatic colorectal cancer (mCRC). Targeted molecular therapies such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) are becoming more precise, targeting specifically for cancer therapeu...

Full description

Bibliographic Details
Main Authors: Thomanai Lamtha, Sucheewin Krobthong, Yodying Yingchutrakul, Pawitrabhorn Samutrtai, Christopher Gerner, Lueacha Tabtimmai, Kiattawee Choowongkomon
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Proteome Science
Subjects:
Antibodies
Gefitinib
SW480
Tyrosine kinase inhibitors
Protein interactions
LC–MS/MS
Online Access:https://doi.org/10.1186/s12953-022-00190-6

Internet

https://doi.org/10.1186/s12953-022-00190-6

Similar Items